Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Comment by blogon Jun 21, 2006 6:04pm
339 Views
Post# 11018360

RE: Key is Renal Data or Head to Head

RE: Key is Renal Data or Head to Head“The answer could (?) also be that ISA247 is a threat to Roche's CellCept. If trans ISA247 works, then perhaps CellCept is not needed in transplantation, as it is currently used in conjunction with Cyclosporin.” This is true, could you image the advantage of ISA247 if it could dampen the immune system enough without toxicity to drop just one drug from the cocktail. This would be welcome in the transplant community and it’s very possible.
Bullboard Posts